Prior treatment with α-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia

Haematologica

Volumn 83, Issue 3, 1998, Pages 231-236

  Zuffa, Eliana ^a   Bandini, Giuseppe ^b   Bonini, Alessandro ^b   Santucci, Maria Alessandra ^b   Martinelli, Giovanni ^b   Rosti, Gianantonio ^b   Testoni, Nicoletta ^b   Zaccaria, Alfonso ^a   Tura, Sante ^b  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

interferon; Allogeneic BMT; CML in chronic phase

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN A; METHOTREXATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MORTALITY; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0031969517     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Santucci MA, Saglio G, Tura S. Pathogenesis and progression of chronic myeloid leukemia. Haematologica 1996; 81:63-76.
2. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human α-interferon in chronic myeloid leukemia. Blood 1987; 69:1280-8.
3. The Italian Cooperative Study Group on CML Interferon α-2A as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-5.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986. Br J Haematol 1993; 85:292-9.
5. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 1992; 77:204-14.
6. Santucci MA, Visani G, Russo D, et al. In vitro activity of alpha-interferon on granulocyte-macrophage precursors in chronic myeloid leukemia (CML): correlation with clinical responsiveness. Leuk Lymphoma 1992; 6:155-60.
7. Santucci MA, Soligo D, Pileri S, Zuffa E, Testoni N, Tura S. Interferon-α affects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk Lymphoma 1993; 11(suppl. 1):113-8.
8. Dowding C, Guo AP, Osterholtz J, Siczkowski M, Goldman M, Gordon M. Interferon-α overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78:499-505.
9. Upadhyaya G, Guba SC, Sih SA, et al. Interferon-alpha restore the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88:2131-6.
10. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J Clin Invest 1994; 94:384-91.
11. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994; 84:4142-50.
12. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 1991; 78:2400-6.
13. Muller CA, Waltz J, Zinser R, Buhring HJ, Steinke B, Schmidt H. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-α treatment. Ann of Hematol 1991; 63:259-63.
14. Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S. Autoimmune mediated thrombocytopenia associated with the use of interferon-α in chronic myeloid leukemia. Haematologica 1996; 81:533-5.
15. Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon alpha therapy on the outcome of allogeneic transplantation for chronic myelogenous leukemia. J Clin Oncol 1993; 11:1055-61.
16. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85:2981-90.
17. Bandini G, Belardinelli A, Rosti G, et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adult with haematological malignancies. Bone Marrow Transpl 1994; 13:577-81.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18:295-304.
19. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host syndrome in man. Am J Pathol 1978; 91:545-70.
20. Clift R, Goldman J, Gratwohl A, Horowitz MM. Proposal for standardized reporting of result of bone marrow transplantation for leukemia. Bone Marrow Transplant 1989; 4:445-8.
21. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
22. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39.
23. th Annual Meeting of the EBMT, Stockholm, May 31-June 3, 1992. n. 246.
24. Zuffa E, Bandini G, Bonini A, et al. Outcome of allogeneic transplant in CML patients previously treated with α-interferon. Analysis in a single institution. Bone Marrow Transplant 1995; 15(suppl.2):95.
25. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79-91.
26. Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80:1352-7.
27. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036-43.
28. Galimberti M, Polchi P, Lucarelli G, et al. Allogeneic marrow transplant in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Bone Marrow Transplant 1994; 13:197-201.
29. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase. Blood 1993; 82:2235-8.